ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 479,40
-0,68%
Dow Jones
39 118,86
-0,12%
DAX
18 235,45
0,17%
Brent Oil
84,85
0,00%
Bitcoin
60 941,16
1,04%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Atossa Therapeutics Inc (ATOS)

  7. Atossa Therapeutics Inc (ATOS) Actualités

ATOS

Atossa Therapeutics (ATOS)

Atossa Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ATOS
DateHeureSourceTitreSymboleSociété
28/06/202414h30GlobeNewswire Inc.Atossa Therapeutics Announces Updated Protocol for Clinical Trial Evaluating (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
17/06/202414h30GlobeNewswire Inc.Atossa Set to Join Russell 3000® Index Effective June 28, 2024NASDAQ:ATOSAtossa Therapeutics Inc
05/06/202414h30GlobeNewswire Inc.Atossa to Present at the Sidoti Small-Cap Investor ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
28/05/202414h30GlobeNewswire Inc.Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment ModelNASDAQ:ATOSAtossa Therapeutics Inc
24/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ATOSAtossa Therapeutics Inc
23/05/202415h00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
15/05/202414h30GlobeNewswire Inc.Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
14/05/202422h46Edgar (US Regulatory)Form DEL AM - Delaying amendmentNASDAQ:ATOSAtossa Therapeutics Inc
13/05/202422h05Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ATOSAtossa Therapeutics Inc
13/05/202415h05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ATOSAtossa Therapeutics Inc
13/05/202415h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ATOSAtossa Therapeutics Inc
13/05/202414h50GlobeNewswire Inc.Atossa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
10/05/202415h04Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:ATOSAtossa Therapeutics Inc
10/05/202415h00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:ATOSAtossa Therapeutics Inc
07/05/202414h30GlobeNewswire Inc.Atossa Therapeutics Announces Support of New Breast Cancer Screening GuidelinesNASDAQ:ATOSAtossa Therapeutics Inc
29/04/202414h30GlobeNewswire Inc.Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
15/04/202414h30GlobeNewswire Inc.Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast CancerNASDAQ:ATOSAtossa Therapeutics Inc
11/04/202414h30GlobeNewswire Inc.Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare ConferenceNASDAQ:ATOSAtossa Therapeutics Inc
09/04/202417h59GlobeNewswire Inc.Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-EndoxifenNASDAQ:ATOSAtossa Therapeutics Inc
01/04/202422h00GlobeNewswire Inc.Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:ATOSAtossa Therapeutics Inc
19/03/202413h30GlobeNewswire Inc.Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer PatientNASDAQ:ATOSAtossa Therapeutics Inc
18/03/202413h30GlobeNewswire Inc.Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing RequirementsNASDAQ:ATOSAtossa Therapeutics Inc
12/03/202413h30GlobeNewswire Inc.Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of DirectorsNASDAQ:ATOSAtossa Therapeutics Inc
22/02/202414h30GlobeNewswire Inc.Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS StudyNASDAQ:ATOSAtossa Therapeutics Inc
07/02/202414h30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
09/01/202414h30GlobeNewswire Inc.Atossa Therapeutics Issues Letter to ShareholdersNASDAQ:ATOSAtossa Therapeutics Inc
04/12/202314h30GlobeNewswire Inc.Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical DirectorNASDAQ:ATOSAtossa Therapeutics Inc
20/11/202314h30GlobeNewswire Inc.Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical TrialNASDAQ:ATOSAtossa Therapeutics Inc
15/11/202323h03Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ATOSAtossa Therapeutics Inc
15/11/202322h15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ATOSAtossa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ATOS

Dernières Valeurs Consultées

EU
CAP
Capgemini
EU
RI
Pernod Ricard
EU
ACA
Credit Agricole
NYSE
DIS
Walt Disney
EU
ORA
Orange
EU
BN
Danone
NYSE
KO
Coca Cola
SPI
SP500
S&P 500
EU
HO
Thales
NYSE
MRK
Merck
NYSE
JPM
JP Morgan Chase
EU
ML
Michelin
NASDAQ
NVDA
NVIDIA
EU
CS
Axa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés